Yes I'm still awaiting CRSP data from a scientific conference and not selective data to boost share price and then raise cash with dilution.
2.4B market cap for CRSP is insane given current situation.
It has same market cap as BLUE that actually has beta thal and sickle cell treatment on the market and a multiple myeloma phase 3 getting filed for approval soon.
CRSP has data on 2 patients haha for the same indications haha.
Speaking of BLUE..that is an insanely low valuation and is ripe for a buyout if they cant raise cash this year..
Win/win either way with rebound from low valuation or buyout